During the last session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s traded shares were 0.88 million, with the beta value of the company hitting 2.77. At the end of the trading day, the stock’s price was $7.79, reflecting an intraday loss of -2.50% or -$0.2. The 52-week high for the FDMT share is $36.25, that puts it down -365.34 from that peak though still a striking 6.03% gain since the share price plummeted to a 52-week low of $7.32. The company’s market capitalization is $360.11M, and the average intraday trading volume over the past 10 days was 1.02 million shares, and the average trade volume was 851.84K shares over the past three months.
4D Molecular Therapeutics Inc (FDMT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.64. FDMT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.83.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
4D Molecular Therapeutics Inc (FDMT) registered a -2.50% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -2.50% in intraday trading to $7.79, hitting a weekly high. The stock’s 5-day price performance is -11.78%, and it has moved by -5.12% in 30 days. Based on these gigs, the overall price performance for the year is -35.67%. The short interest in 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is 8.18 million shares and it means that shorts have 9.89 day(s) to cover.
The consensus price target of analysts on Wall Street is $40, which implies an increase of 80.53% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $30 and $58 respectively. As a result, FDMT is trading at a discount of -644.54% off the target high and -285.11% off the low.
4D Molecular Therapeutics Inc (FDMT) estimates and forecasts
Statistics show that 4D Molecular Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. 4D Molecular Therapeutics Inc (FDMT) shares have gone down -69.03% during the last six months, with a year-to-date growth rate less than the industry average at -12.40% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -8.04% this quarter and then drop -23.86% in the quarter after that. In the rating firms’ projections, revenue will decrease -93.32% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 2.2M as predicted by 6 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 176k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled -19k and 28k respectively. In this case, analysts expect current quarter sales to grow by 11,682.47% and then jump by 528.57% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -46.35%. While earnings are projected to return -13.07% in 2024.
FDMT Dividends
4D Molecular Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
4D Molecular Therapeutics Inc insiders own 3.91% of total outstanding shares while institutional holders control 115.28%, with the float percentage being 119.98%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 215.0 institutions own stock in it. As of 2024-06-30, the company held over 5.1 million shares (or 10.3471% of all shares), a total value of $107.01 million in shares.
The next largest institutional holding, with 4.9 million shares, is of BLACKROCK INC.’s that is approximately 9.9385% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $102.79 million.
Also, the Mutual Funds coming in first place with the largest holdings of 4D Molecular Therapeutics Inc (FDMT) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.46 shares. This amounts to just over 3.15 percent of the company’s overall shares, with a $11.34 million market value. The same data shows that the other fund manager holds slightly less at 1.29, or about 2.80% of the stock, which is worth about $10.09 million.
